{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:05:46Z","timestamp":1776693946578,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,11]],"date-time":"2005-12-11T00:00:00Z","timestamp":1134259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/nm1337","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T15:09:34Z","timestamp":1134400174000},"page":"122-127","source":"Crossref","is-referenced-by-count":505,"title":["Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"George V","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek S","family":"Welsbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Fueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L","family":"Sawyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,11]]},"reference":[{"key":"BFnm1337_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins, M.B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909\u2013918 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnm1337_CR2","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim, W.Y. & Kaelin, W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991\u20135004 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnm1337_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W.G., Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm1337_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","volume":"1","author":"JK Maranchie","year":"2002","unstructured":"Maranchie, J.K. et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247\u2013255 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm1337_CR5","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson, C.C. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004\u20137014 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm1337_CR6","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong, H. et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541\u20131545 (2000).","journal-title":"Cancer Res."},{"key":"BFnm1337_CR7","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C. & Semenza, G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995\u20134004 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm1337_CR8","first-page":"4804","volume":"55","author":"F Chen","year":"1995","unstructured":"Chen, F. et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 55, 4804\u20134807 (1995).","journal-title":"Cancer Res."},{"key":"BFnm1337_CR9","doi-asserted-by":"publisher","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","volume":"95","author":"O Iliopoulos","year":"1998","unstructured":"Iliopoulos, O., Ohh, M. & Kaelin, W.G., Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA 95, 11661\u201311666 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1337_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","volume":"1","author":"SJ Mandriota","year":"2002","unstructured":"Mandriota, S.J. et al. HIF activation identifies early lesions in VHL kidneys. Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459\u2013468 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm1337_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.biochem.74.082803.133142","volume":"74","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74, 115\u2013128 (2005).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnm1337_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128\u2013135 (2002).","journal-title":"Nat. Med."},{"key":"BFnm1337_CR13","doi-asserted-by":"publisher","first-page":"29655","DOI":"10.1074\/jbc.M212770200","volume":"278","author":"AM Arsham","year":"2003","unstructured":"Arsham, A.M., Howell, J.J. & Simon, M.C. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278, 29655\u201329660 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnm1337_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcb.20067","volume":"92","author":"O Aprelikova","year":"2004","unstructured":"Aprelikova, O. et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J. Cell. Biochem. 92, 491\u2013501 (2004).","journal-title":"J. Cell. Biochem."},{"key":"BFnm1337_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder, P.K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594\u2013601 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1337_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1464-410X.2003.04284.x","volume":"92","author":"SF Hain","year":"2003","unstructured":"Hain, S.F. & Maisey, M.N. Positron emission tomography for urological tumours. BJU Int. 92, 159\u2013164 (2003).","journal-title":"BJU Int."},{"issue":"Suppl. 1","key":"BFnm1337_CR17","first-page":"28","volume":"97","author":"H Joensuu","year":"2002","unstructured":"Joensuu, H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med. Klin. (Munich) 97 Suppl. 1, 28\u201330 (2002).","journal-title":"Med. Klin. (Munich)"},{"key":"BFnm1337_CR18","first-page":"17","volume":"45","author":"I Gayed","year":"2004","unstructured":"Gayed, I. et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45, 17\u201321 (2004).","journal-title":"J. Nucl. Med."},{"key":"BFnm1337_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391\u2013400 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnm1337_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1535-6108(03)00194-6","volume":"4","author":"B Blouw","year":"2003","unstructured":"Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133\u2013146 (2003).","journal-title":"Cancer Cell"},{"key":"BFnm1337_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein, I.B. Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 297, 63\u201364 (2002).","journal-title":"Science"},{"key":"BFnm1337_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.cco.0000143964.74936.d1","volume":"16","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky, E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564\u2013575 (2004).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnm1337_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C.D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1337_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1095-0397(01)00068-1","volume":"4","author":"N Satyamurthy","year":"2002","unstructured":"Satyamurthy, N., Amarasekera, B., Alvord, C.W., Barrio, J.R. & Phelps, M.E. Tantalum [18O]water target for the production of [18F]fluoride with high reactivity for the preparation of 2-deoxy-2-[18F]fluoro-D-glucose. Mol. Imaging Biol. 4, 65\u201370 (2002).","journal-title":"Mol. Imaging Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1337","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:26:06Z","timestamp":1684448766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BFnm1337"],"URL":"https:\/\/doi.org\/10.1038\/nm1337","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,11]]}}}